Early TTFields Use in Glioblastoma Patients Does Not Improve Survival
Starting tumor treating fields during chemoradiotherapy does not increase survival in newly diagnosed glioblastoma patients, though some subgroups may need further study.
Patients with glioblastoma and their caregivers; evidence from a clinical trial
Study design and population
The trial involved patients with newly diagnosed glioblastoma who received tumor treating fields alongside standard chemoradiotherapy.
Key finding
The use of tumor treating fields at the start of treatment did not lead to improved survival rates.
Subgroup considerations
Some subgroups showed potential for further investigation, though the overall result was not significant.
Common questions
Does early use of TTFields help glioblastoma patients survive longer?
No, early use of TTFields during chemoradiotherapy did not improve survival in newly diagnosed glioblastoma patients.
Are there any subgroups that might benefit from TTFields?
Some subgroups showed potential for further study, but the overall trial did not find a survival benefit.
Sources
- Earlier Use of TTFields Misses Mark in Glioblastoma Medscape · medscape.com
Headlines and links belong to the publishers listed above. The summary above is written by The Health Brief; see how this works.
